<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments on: One Step Closer to Personalized Medicine</title>
	<atom:link href="http://pcshannon.com/2007/06/16/one-step-closer-to-personalized-medicine/feed/" rel="self" type="application/rss+xml" />
	<link>http://pcshannon.com/2007/06/16/one-step-closer-to-personalized-medicine/</link>
	<description>Don't mind if I do</description>
	<pubDate>Thu, 04 Dec 2008 01:11:46 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6.1</generator>
		<item>
		<title>By: docwedley</title>
		<link>http://pcshannon.com/2007/06/16/one-step-closer-to-personalized-medicine/#comment-505</link>
		<dc:creator>docwedley</dc:creator>
		<pubDate>Fri, 13 Jul 2007 15:12:10 +0000</pubDate>
		<guid isPermaLink="false">http://www.pcshannon.com/blog/2007/06/one-step-closer-to-personalized-medicine/#comment-505</guid>
		<description>It is, of course, my personal hope that pharmacogenomics really takes off. What we have now in terms of tailoring chemotherapies for certain cancers based upon receptor phenotypes is already revolutionizing oncology. That's the draw of molecular pathology, for sure, and hopefully just the tip of the iceberg. Its easy to concieve of drugs which might benefit some people and not others, based on enzyme / receptor polymorphisms, that might fall through the cracks if simply studied on a population level, but when the response can be correlated to the gene profile of the individual, then we'll have some truly powerful new weapons to fight disease. 

DocWedley</description>
		<content:encoded><![CDATA[<p>It is, of course, my personal hope that pharmacogenomics really takes off. What we have now in terms of tailoring chemotherapies for certain cancers based upon receptor phenotypes is already revolutionizing oncology. That&#8217;s the draw of molecular pathology, for sure, and hopefully just the tip of the iceberg. Its easy to concieve of drugs which might benefit some people and not others, based on enzyme / receptor polymorphisms, that might fall through the cracks if simply studied on a population level, but when the response can be correlated to the gene profile of the individual, then we&#8217;ll have some truly powerful new weapons to fight disease. </p>
<p>DocWedley</p>
]]></content:encoded>
	</item>
</channel>
</rss>
